ACH-126443 Achillion/Yale University.
Achillion, under license from Vion, is developing the nucleoside analog ACH-126443 (beta-L-Fd4C), a reverse transcriptase (RT) inhibitor, for the potential treatment of HIV and hepatitis B virus (HBV) infection. The compound is one of a series of antiviral compounds developed by Yale University [213319]. By February 2002, it had entered phase II trials for chronic HBV infection [435422]; these were ongoing in June 2002, by which time, additional phase II clinical studies for chronic HBV infection had been planned [452185], [454316].